Zydus Sunshine Lifesciences is set to invest more than $20 million in establishing a dedicated pharmaceutical manufacturing facility in Sri Lanka, marking a major expansion of regional medicine production and healthcare infrastructure.
The project represents a substantial foreign direct investment targeted at expanding domestic drug manufacturing capabilities. The new production plant aims to boost regional pharmaceutical supply chains and enhance local accessibility to essential healthcare products.
Key Developments
- Zydus Sunshine Lifesciences commits over $20 million to build a Sri Lankan pharma plant.
- The initiative focuses on establishing modern domestic pharmaceutical manufacturing capabilities.
- The project supports regional health security and industrial investment in the healthcare sector.
This multi-million-dollar investment reinforces Sri Lanka’s position as an emerging destination for specialized industrial capital. By expanding local pharmaceutical manufacturing capacities, the initiative helps mitigate supply chain vulnerabilities, reduce reliance on imported finished medicines, and build sustainable regional capacity for critical health products.